[ad_1]
The Corsican regional health agency held a videoconference this Friday on the presentation of the SARS-CoV-2 molecule and vaccines aimed at population immunity.
SARS-CoV-2, its origin
Covid-19 has been wreaking havoc in the world for just over a year.
Doctor Poitrenaud, general practitioner at La Miséricorde hospital, says more.
This virus, resulting from “family of the Coronaviridae” has a “wrapped ribonucleic acid (RNA)” and it is similar to a virus that is genetically similar to those that infect bats.
However, “no direct viral transmission” has not yet been proven with the latter, but two hypotheses persist:
– SARS-CoV-2 was broadcast “to man through an intermediate host species (zoonosis)”, like the pangolin?
– SARS-CoV-2 was broadcast “circulating for several years in humans, at low noise, until a recent mutation made it more virulent and pathogenic” ?
Based on its genetics, Covid-19 can therefore mutate more rapidly and this is what has been observed “ten mutations” its. For example, his “transmission between man and mink, and mink to man”.
How does the body react to Covid-19?
SARS-CoV-2 contaminates through the air. Since, “attaches itself to its receiver and hijacks cellular production tools”. It then multiplies and infects other nearby cells.
An inflammatory response is triggered by the infected cell and the antibodies try to neutralize the infection that creates damage to the lungs.
According to the Institut Pasteur after a study conducted on “308 hospital staff members who had mild SARS-CoV-2”, neutralizing antibodies are present up to six months after contamination in 84% of them.
However, the level of these antibodies decreases “faster in men than women”.
Vaccines to combat SARS-CoV-2
The vaccination program is scheduled to start in early 2021.
256 “vaccine candidates” were submitted less than a year after the pandemic began. Only 10 of them have reached stage 3, i.e. “randomized clinical trial comparing two treatments” explains Dr. Mahamat, a hepatologist.
Those with the highest rate of effectiveness are the two American Pfizer-BioNTech and Moderna / NIH, respectively carried out on 43,661 participants and 30,000 participants and presenting for an eight failures, and the other five.
Both are of the RNA type and require two doses of injections. The second dose is performed on D + 21, in order to generate complete immunity on D + 28.
However, the conservation methods are different.
Pfizer-BioNTech vaccine should be stored at –70 ° C for a long time and at + 4 ° C for 5 days.
Modern / NIH, at -20 ° C for a long time and + 4 ° C for thirty days.
Special technologies are therefore needed, and France plans to finance freezers for healthcare facilities.
And the vaccination course in Corsica?
MA (Marketing Authorization) responses on submitted vaccines will fall on December 29th.
The island’s hospitals hope for a “first supply flow in January”and a first vaccination for “fragile people” available from then on. This first phase aims at “avoid hospitalizations and deaths”.
In Corsica, 36,000 people are over 75 and 33,000 are aged between 65 and 74.
Therefore, 12,000 vaccination doses are planned for the entire island during the first phase.
At the end of the second phase scheduled between February and March, a maximum of 36,000 people will be vaccinated. Namely the one among the sayings “fragile people”, some of them will have already been vaccinated in EHPAD.
For now, therefore, “do not release barrier gestures” remember the ARS.
The portion of the population that does not present particular health risks cannot therefore be vaccinated before the summer period, subject to authorization for the marketing of a vaccine.
This vaccination will be covered by health insurance and general practitioners appear, a priori, to be the key to this large-scale system, i.e. phase 3.
Source link
